secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akili, Inc. (—)
CIK:        0001850266
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001140361-24-032101
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akili completes acquisition by Virtual Therapeutics at $0.4340 per share; stock to be delisted
--------------------------------------------------------------------------------

- Tender offer closed with 69,674,538 shares (88.2%) validly tendered at $0.4340 per share; merger completed July 2, 2024.
- All outstanding shares converted to right to receive Offer Price; company becomes wholly owned subsidiary of Virtual Therapeutics.
- Board of directors resigned; Daniel J. Elenbaas becomes sole director; Matt McIntire named Treasurer and Secretary.
- Nasdaq listing suspended; Form 25 to be filed to delist shares; registration to be terminated on Form 15.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/ny20031954x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-032101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer